The well-known anti-human VEGFA antibody bevacizumab has been shown not only to reduce tumor edema, angiogenesis, and disease burden but also to provoke adaptive escape mechanisms involving hypoxia by pruning tumor blood vessels, switching to a glycolytic metabolism, neo-vascularization, and/or infiltrative tumor growth (Norden et al., 2008; Eelen et al., 2020). Here, VEGFA is linked to neoplasm.